Board appointment at K-V Pharmaceutical
This article was originally published in Scrip
K-V Pharmaceutical Company (US) has elected Dr David Sidransky as a new independent member of the board of directors. Dr Sidransky replaces John Sampson, whose resignation from the board was effective upon his appointment. Dr Sidransky is professor of oncology, otolaryngology, cellular and molecular medicine, urology, genetics and pathology at John Hopkins University and Hospital.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.